Analysis of national skin cancer expenditures in the United States Medicare population, 2013
To the Editor: Approximately 3 million adults in the United States are treated annually for skin cancer, costing nearly $8.1 billion per year.
1,2 Nonmelanoma skin cancer and malignant melanoma (MM) are the fifth and ninth most costly dermatologic conditions, respectively. 3 The few studies that have evaluated allocation of resources on skin cancer have underestimated total cost, as they included only payments to dermatologists. The goal of this study was to analyze 2013 Medicare skin cancer spending by diagnosis and procedure.
The 2013 Medicare Limited Data Set Standard Analytic File 5% Sample Physician Supplier was queried for all claims filed for International Classification of Diseases, Ninth Revision, Clinical Modification codes for MM, squamous cell carcinoma (SCC), basal cell carcinoma (BCC), other malignant neoplasms of the skin, carcinoma in situ of the skin (CIS), actinic keratosis (AK), and neoplasm of uncertain behavior of the skin. All payments J AM ACAD DERMATOL VOLUME 80, NUMBER 1 associated with more than 1570 Current Procedural Terminology codes were classified into 9 treatment categories (evaluation and management, biopsy, surgical procedures, destruction, laboratory and pathology, radiology and other imaging procedures, systemic therapy, radiation, and other) and 22 subcategories by diagnosis. Spending on each subcategory was summed to calculate total and mean spending per person per diagnosis. All analyses were performed with SAS software (version 9.4, SAS Institute Inc, Cary, NC). The Partners Human Research Committee exempted this study.
A total of $2.5 billion was spent on skin cancererelated diagnoses in Medicare patients in 2013. Half (49%) of this spending was on BCC ($715 million) and SCC ($525 million), which are highly prevalent cancers. Total spending on AK ($554 million) narrowly exceeded that on SCC, with 76% of AK resources allocated to destruction (Fig 1) . MM was the costliest diagnosis per person per year ($1241), followed by BCC ($689) and SCC ($649). The percentages of total spending on skin cancer per diagnosis were as follows BCC, 29%; AK, 22%; SCC, 21%; neoplasm of uncertain behavior of the skin, 15%; MM, 7%; CIS, 3.5%; and other, 3.5%. Mohs micrographic surgical excision accounted for 17.5% of spending ($438 million). Approximately half of spending on MM (48%) was for systemic therapy. Forty percent of spending on MM ($74 million) was allocated to ipilimumab for 920 patients (0.6% of patients with melanoma) at a cost of $80 thousand per patient treated (Table I ).
In conclusion, of the $2.5 billion spent on skin cancererelated diagnoses, the majority (72%) was divided approximately equally between treatment of BCC, SCC, and AK. Because the costs of topical prescription drugs such as 5-fluorouracil were not included in this analysis, the costs of treatment of AKs, CIS, and superficial BCCs are underestimated. The largest fraction (40%) of money spent on MM is Survey analysis on the management of moderately dysplastic nevi among academic dermatologists across the United States
To the Editor: Currently there are no clinical guidelines for the management of moderately dysplastic nevi (DN), and the decision to observe, rebiopsy, or excise remains up to the discretion of the dermatologist. Many dermatopathologists do not embrace the grading system of mild, moderate, or severe dysplasia but simply comment on the presence of architectural or cytologic atypia. In the literature to date, there is significant variation and lack of consensus on the management of moderate DN, [1] [2] [3] the histologic criteria, and the use of the term moderate DN. In fact, low interobserver reproducibility in the classification of dysplastic nevi between dermatopathologists viewing the same lesion, demonstrated by low kappa values in both experienced and less experienced dermatopathologists, has been demonstrated previously. 4 The purpose of this study was to better understand the management of biopsy-proven moderate DN among academic dermatologists, given their critical role in influencing the future practice guidelines of dermatology.
After University of South Florida Institutional Review Board approval was obtained, an anonymous survey of 12 multiple-choice questions was e-mailed to the 385 members of the Association of Professors of Dermatology. Respondents were asked to indicate how they would manage biopsy-proven moderate DN in 9 different situations, selecting from 5 different management options (Tables I and II). A total of 131 (34%) members (52 programs) of the Association of Professors of Dermatology listserv completed the survey, with 12 respondents indicating that their institution did not use the term moderate DN. We found notable variability in the management of biopsy-proven moderate DN among academic dermatologists (Tables I and II) . The only scenario with high concordance was in the management of moderately DN with clear biopsy margins and without visible pigment, with 93% (124) of respondents choosing clinical monitoring. However, 5% of respondents still chose surgical excision with 2e3-mm margins, highlighting the lack of consensus.
Our results show varied management depending on biopsy margin and residual pigment status; however, certain trends can be recognized. In all scenarios with a positive biopsy margin, the majority of respondents chose a second procedure over clinical monitoring (Table II) , irrespective of pigment at the biopsy site. Both repeat biopsy and excision at various margins are done with the intent to obtain a histologically clear margin; however, each subcategorization of these procedures can be used to reflect the comfort level of practitioners with moderate DN.
The absence of visible pigment in a positive biopsy margin (lateral, deep, deep and lateral) markedly increased the percentage of respondents who chose clinical monitoring (45%, 40%, 37%, respectively). Surgical excision (2e3-mm margin)
